{"medgen_id":"C0220988","type":"Finding","keywords":[],"alternate_names":["Increased urinary xanthine"],"attribute_content":[],"alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0010934\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0000721\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0010934\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Increased urinary xanthine\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0010934\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"190919008\",\"ref_field\":\"name\"}"],"id":"28847","name":"Xanthinuria"}
{"medgen_id":"C1843367","type":"Finding","keywords":[],"gard_id":"11963","content":"{\"Citation\":{\"@Abbrev\":\"AAN/CNS, 2011\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"21956720\",\"@Source\":\"PubMed\"}}}","alternate_names":["Dull intelligence","Low intelligence","Mental deficiency","Mental retardation, nonspecific","Mental-retardation","Nonprogressive intellectual disability","Nonprogressive mental retardation","Poor school performance"],"attribute_content":[],"alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000730\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001249\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001267\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001286\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002122\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002192\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002316\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002382\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002386\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002402\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002458\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002482\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002499\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002543\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003767\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006833\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007154\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007176\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007180\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:HP:0001249\",\"type\":\"secondary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0001071\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001249\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Dull intelligence\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001249\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Low intelligence\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001249\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Mental deficiency\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001249\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Mental retardation, nonspecific\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001249\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Mental-retardation\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001249\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Nonprogressive intellectual disability\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001249\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Nonprogressive mental retardation\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001249\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Poor school performance\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"11963\",\"ref_field\":\"gard_id\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001249\",\"ref_field\":\"name\"}"],"id":"22261","name":"Intellectual disability"}
{"medgen_id":"C0265740","type":"Finding","keywords":[],"gard_id":"364","alternate_names":["Absent nose","Arrhinia","Congenital absence of the nose","Failure of development of nose","Missing nose","Nasal underdevelopment","Nose agenesia","Underdevelopment of nose"],"attribute_content":[],"alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009927\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0015237\"}","{\"db\":\"Orphanet\",\"id\":\"1134\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009927\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Absent nose\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009927\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Arrhinia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009927\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Failure of development of nose\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009927\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Missing nose\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009927\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Nasal underdevelopment\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009927\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Underdevelopment of nose\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"364\",\"ref_field\":\"gard_id\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009927\",\"ref_field\":\"name\"}"],"id":"27888","name":"Aplasia of the nose"}
{"medgen_id":"C1879321","type":"Disease","keywords":[],"gard_id":"527","alternate_names":["Acute myeloblastic leukemia with maturation"],"attribute_content":[],"alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0020320\"}","{\"db\":\"Orphanet\",\"id\":\"98834\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"527\",\"ref_field\":\"gard_id\"}"],"id":"37847","name":"Acute myeloid leukemia with maturation"}
{"medgen_id":"CN280942","type":"Disease","keywords":[],"alternate_names":[],"attribute_content":[],"alternate_symbols":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618891\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"123859.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"123859.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"123859.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"123859.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"123859.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618891\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618891\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"symbol":"MDBH","id":"52486","name":"MICROCEPHALY, DEVELOPMENTAL DELAY, AND BRITTLE HAIR SYNDROME"}
{"medgen_id":"C1853139","type":"Disease","keywords":[],"gard_id":"10201","alternate_names":[],"attribute_content":[],"alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012543\"}","{\"db\":\"OMIM\",\"id\":\"610708\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"98673\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10201\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Optic+atrophy+5/5383\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"610708\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"symbol":"OPA5","id":"5681","name":"Optic atrophy 5"}
{"medgen_id":"C4225307","type":"Disease","keywords":[],"alternate_names":[],"attribute_content":[],"alternate_symbols":["GRDF"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014663\"}","{\"db\":\"OMIM\",\"id\":\"616489\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"616489\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"GRDF\"}","{\"db\":\"OMIM\",\"id\":\"616489\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"symbol":"SRS3","id":"33605","name":"Growth restriction, severe, with distinctive facies"}
{"medgen_id":"C3151039","type":"Disease","keywords":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301486\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1309\",\"@Source\":\"BookShelf\"}]}}","alternate_names":[],"attribute_content":[],"alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0000911\"}","{\"db\":\"Orphanet\",\"id\":\"154\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cardiomyopathy%2C+dilated%2C+1t/7895\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613740\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"symbol":"CMD1T","id":"11050","name":"Dilated cardiomyopathy 1T"}
{"medgen_id":"C1832388","type":"Disease","keywords":["Neoplasm"],"alternate_names":["Familial thrombocytopenia with propensity to acute myelogenous leukemia","Platelet disorder, Aspirin-like"],"attribute_content":[],"alternate_symbols":["FPD/AML"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0100083\"}","{\"db\":\"OMIM\",\"id\":\"601399\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"71290\"}","{\"db\":\"OMIM\",\"id\":\"601399\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FPD/AML\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Familial+Platelet+Disorder+with+Associated+Myeloid+Malignancy/2765\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601399\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"symbol":"FPDMM","id":"3980","name":"Familial platelet disorder with associated myeloid malignancy"}
{"medgen_id":"C1970879","type":"Disease","keywords":[],"gard_id":"12915","alternate_names":["IMMUNODEFICIENCY 33"],"attribute_content":[],"alternate_symbols":["IPD2"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010386\"}","{\"db\":\"OMIM\",\"id\":\"300636\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"319605\"}","{\"db\":\"Orphanet\",\"id\":\"319612\"}","{\"db\":\"OMIM\",\"id\":\"300248.0019\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 33\"}","{\"db\":\"OMIM\",\"id\":\"300248.0021\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 33\"}","{\"db\":\"OMIM\",\"id\":\"300248.0022\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 33\"}","{\"db\":\"OMIM\",\"id\":\"300248.0025\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 33\"}","{\"db\":\"OMIM\",\"id\":\"300248.0026\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 33\"}","{\"db\":\"OMIM\",\"id\":\"300248.0029\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 33\"}","{\"db\":\"OMIM\",\"id\":\"300248.0030\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 33\"}","{\"db\":\"OMIM\",\"id\":\"300248.0032\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 33\"}","{\"db\":\"OMIM\",\"id\":\"300636\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 33\"}","{\"db\":\"OMIM\",\"id\":\"300636\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"IPD2\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"12915\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"X-linked+familial+atypical+mycobacteriosis%2C+type+1/9486\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"300636\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"symbol":"IMD33","id":"569","name":"Familial atypical mycobacteriosis, type 1, X-linked"}
{"medgen_id":"C3277900","type":"Disease","keywords":[],"alternate_names":["ANONYCHIA TOTALIS","ANONYCHIA/HYPONYCHIA CONGENITA","Absent nails","Aplastic nails","Hyponychia congenita","NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4"],"attribute_content":[],"alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001798\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007593\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008384\",\"type\":\"secondary\"}","{\"db\":\"OMIM\",\"id\":\"206800\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"79143\"}","{\"db\":\"Orphanet\",\"id\":\"94150\"}","{\"db\":\"OMIM\",\"id\":\"206800\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ANONYCHIA TOTALIS\"}","{\"db\":\"OMIM\",\"id\":\"206800\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ANONYCHIA/HYPONYCHIA CONGENITA\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001798\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Absent nails\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001798\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Aplastic nails\"}","{\"db\":\"OMIM\",\"id\":\"206800\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Anonychia+Congenita/488\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001798\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"23610003\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"206800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"symbol":"NDNC4","id":"411","name":"Anonychia"}
{"medgen_id":"C1846006","type":"Disease","keywords":[],"alternate_names":["ECTODERMAL DYSPLASIA AND IMMUNE DEFICIENCY 1","ECTODERMAL DYSPLASIA, ANHIDROTIC, WITH IMMUNE DEFICIENCY","Hypohidrotic ectodermal dysplasia with immune deficiency"],"attribute_content":[],"alternate_symbols":["HED-ID","HEDID","OLEDAID","XHMED"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0020740\"}","{\"db\":\"OMIM\",\"id\":\"300291\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"238468\"}","{\"db\":\"Orphanet\",\"id\":\"98813\"}","{\"db\":\"OMIM\",\"id\":\"300248.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ECTODERMAL DYSPLASIA AND IMMUNE DEFICIENCY 1\"}","{\"db\":\"OMIM\",\"id\":\"300291\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ECTODERMAL DYSPLASIA, ANHIDROTIC, WITH IMMUNE DEFICIENCY\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hypohidrotic+ectodermal+dysplasia+with+immune+deficiency/3657\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hypohidrotic ectodermal dysplasia with immune deficiency\"}","{\"db\":\"OMIM\",\"id\":\"300291\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HEDID\"}","{\"db\":\"OMIM\",\"id\":\"300291\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"OLEDAID\"}","{\"db\":\"OMIM\",\"id\":\"300291\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"XHMED\"}","{\"db\":\"OMIM\",\"id\":\"300291\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"symbol":"EDAID1","id":"1582","name":"Ectodermal dysplasia and immunodeficiency 1"}
{"medgen_id":"C1832661","type":"Disease","keywords":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301552\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1378\",\"@Source\":\"BookShelf\"}]}}","alternate_names":["ANOPHTHALMIA, CLINICAL, WITH MILD FACIAL DYSMORPHISM AND VARIABLE MALFORMATIONS OF THE LUNG, HEART, AND DIAPHRAGM","Anophthalmia/microphthalmia and pulmonary hypoplasia","Clinical anophthalmia mild facial dysmorphism lung heart and diaphragm malformations","Matthew Wood syndrome","PULMONARY AGENESIS, MICROPHTHALMIA, AND DIAPHRAGMATIC DEFECT","PULMONARY HYPOPLASIA-DIAPHRAGMATIC HERNIA-ANOPHTHALMIA-CARDIAC DEFECT","Pulmonary agenesis microphthalmi and diaphragmatic defect","Spear syndrome"],"attribute_content":[],"alternate_symbols":["PDAC","PMD"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011010\"}","{\"db\":\"OMIM\",\"id\":\"601186\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2470\"}","{\"db\":\"OMIM\",\"id\":\"601186\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ANOPHTHALMIA, CLINICAL, WITH MILD FACIAL DYSMORPHISM AND VARIABLE MALFORMATIONS OF THE LUNG, HEART, AND DIAPHRAGM\"}","{\"db\":\"OMIM\",\"id\":\"601186\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PULMONARY AGENESIS, MICROPHTHALMIA, AND DIAPHRAGMATIC DEFECT\"}","{\"db\":\"OMIM\",\"id\":\"601186\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PULMONARY HYPOPLASIA-DIAPHRAGMATIC HERNIA-ANOPHTHALMIA-CARDIAC DEFECT\"}","{\"db\":\"OMIM\",\"id\":\"601186\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PDAC\"}","{\"db\":\"OMIM\",\"id\":\"601186\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PMD\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Microphthalmia+syndromic+9/4793\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601186\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"symbol":"MCOPS9","id":"5533","name":"Microphthalmia syndromic 9"}
{"disease_mechanism":"Fabry disease is due to inactivating mutations in the X-linked GLA gene resulting in deficiency of the enzyme Alpha Galactosidase-A.","medgen_id":"C0002986","type":"Disease","keywords":[],"gard_id":"6400","content":"{\"Citation\":[{\"@Type\":\"general\",\"ID\":{\"$\":\"3009617\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301469\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1292\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"HFSA, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20610207\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"12735292\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Eng et al., 2006\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"16980809\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Salviati et al, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2869001\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGentest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21934708\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHA/ASA, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25355838\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23860966\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","alternate_names":["Alpha-galactosidase A deficiency","Anderson-Fabry disease","Angiokeratoma corporis diffusum","Angiokeratoma, diffuse","Ceramide trihexosidase deficiency","Ceramide trihexosidosis","Fabry syndrome","Fabry's disease","GLA deficiency","Hereditary dystopic lipidosis"],"attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000505068\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507480\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507942\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000522527\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000568367\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000514924\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520414\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528516\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000246735\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000260631\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520063\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520447\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528528\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000552214\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556520\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000558532\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000325415\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000512526\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528276\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528500\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528536\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556501\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000551442\"}]}"],"alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010526\"}","{\"db\":\"OMIM\",\"id\":\"301500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"324\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Angiokeratoma corporis diffusum\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fabry+Disease/2690\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"16652001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500007\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6400\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"fabry-disease\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1292\",\"ref_field\":\"public_definition\"}"],"id":"1790","name":"Fabry disease","public_definition":"Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (a-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% a-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype. In contrast, males with greater than 1% a-Gal A activity may have: (1) a cardiac variant phenotype that usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy and arrhythmia, and proteinuria, but without ESRD; or (2) a renal variant phenotype, associated with ESRD but without the skin lesions or pain; or (3) cerebrovascular disease presenting as stroke or transient ischemic attack."}
{"medgen_id":"C1266144","type":"Disease","keywords":[],"gard_id":"8757","content":"{\"Citation\":[{\"@Abbrev\":\"ASCO, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24493721\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"24761742\",\"@Source\":\"PubMed\"},{\"$\":\"NBK196157\",\"@Source\":\"BookShelf\"}]}]}","alternate_names":[],"attribute_content":[],"alternate_symbols":["PPB"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100528\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011014\"}","{\"db\":\"Orphanet\",\"id\":\"64742\"}","{\"db\":\"OMIM\",\"id\":\"601200\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PPB\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8757\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Pleuropulmonary+blastoma/5804\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100528\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK196157\",\"ref_field\":\"public_definition\"}"],"id":"5772","name":"Pleuropulmonary blastoma","public_definition":"DICER1 tumor predisposition (DICER1) is characterized by an increased risk for pleuropulmonary blastoma (PPB), pulmonary cysts, thyroid gland neoplasia (multinodular goiter, adenomas, and/or thyroid cancer), ovarian tumors (Sertoli-Leydig cell tumor, gynandroblastoma, and sarcoma), and cystic nephroma. Less commonly observed tumors include ciliary body medulloepithelioma, nasal chondromesenchymal hamartoma, embryonal rhabdomyosarcoma, pituitary blastoma, pineoblastoma, central nervous system (CNS) sarcoma, other CNS tumors, and presacral malignant teratoid tumor. The majority of tumors occur in individuals younger than age 40 years. PPB typically presents in infants and children younger than age six years. Ovarian sex cord-stromal tumors are most often diagnosed before age 40 years. Cystic nephroma generally presents in young children but has also been reported in adolescents. Additional clinical features that may be seen include macrocephaly, ocular abnormalities, structural anomalies of the kidney and collecting system, and dental anomalies (bulbous crowns)."}
{"medgen_id":"C0175693","type":"Disease","keywords":[],"gard_id":"4870","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301499\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1324\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3111049\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3061987\",\"@Source\":\"pmc\"}}]}","alternate_names":["Silver-Russell dwarfism"],"attribute_content":[],"alternate_symbols":["RSS"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008394\"}","{\"db\":\"OMIM\",\"id\":\"180860\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"813\"}","{\"db\":\"OMIM\",\"id\":\"180860\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"RSS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4870\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Silver-Russell+syndrome/6606\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"russell-silver-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"15069006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1324\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"180860\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"symbol":"SRS1","id":"15879","name":"Russell-Silver syndrome","public_definition":"Silver-Russell Syndrome (SRS) is typically characterized by asymmetric gestational growth restriction resulting in affected individuals being born small for gestational age, with relative macrocephaly at birth (head circumference =1.5 SD above birth weight and/or length), prominent forehead usually with frontal bossing, and frequently body asymmetry. This is followed by postnatal growth failure, and in some cases progressive limb length discrepancy and feeding difficulties. Additional clinical features include triangular facies, fifth-finger clinodactyly, and micrognathia with narrow chin. Except for the limb length asymmetry, the growth failure is proportionate and head growth normal. The average adult height in untreated individuals is ~3.1±1.4 SD below the mean. The Netchine-Harbison Clinical Scoring System (NH-CSS) is a sensitive diagnostic scoring system. Clinical diagnosis can be established in an individual who meets at least four of the NH-CSS clinical criteria – prominent forehead/frontal bossing and relative macrocephaly at birth plus two additional findings – and in whom other disorders have been ruled out."}
{"medgen_id":"C0152419","type":"Disease","keywords":[],"gard_id":"740","alternate_names":["Aortic arch interruption","Aortic arch obstruction","Atretic transverse aortic arch"],"attribute_content":[],"alternate_symbols":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006680\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011611\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0009010\"}","{\"db\":\"Orphanet\",\"id\":\"2299\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0009010\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Aortic arch interruption\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011611\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Aortic arch obstruction\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011611\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Atretic transverse aortic arch\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"740\",\"ref_field\":\"gard_id\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011611\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"critical-congenital-heart-disease\",\"ref_field\":\"public_definition\"}"],"id":"16798","name":"Interrupted aortic arch","public_definition":"Critical congenital heart disease (CCHD) is a term that refers to a group of serious heart defects that are present from birth. These abnormalities result from problems with the formation of one or more parts of the heart during the early stages of embryonic development. CCHD prevents the heart from pumping blood effectively or reduces the amount of oxygen in the blood. As a result, organs and tissues throughout the body do not receive enough oxygen, which can lead to organ damage and life-threatening complications. Individuals with CCHD usually require surgery soon after birth.Although babies with CCHD may appear healthy for the first few hours or days of life, signs and symptoms soon become apparent. These can include an abnormal heart sound during a heartbeat (heart murmur), rapid breathing (tachypnea), low blood pressure (hypotension), low levels of oxygen in the blood (hypoxemia), and a blue or purple tint to the skin caused by a shortage of oxygen (cyanosis). If untreated, CCHD can lead to shock, coma, and death. However, most people with CCHD now survive past infancy due to improvements in early detection, diagnosis, and treatment.Some people with treated CCHD have few related health problems later in life. However, long-term effects of CCHD can include delayed development and reduced stamina during exercise. Adults with these heart defects have an increased risk of abnormal heart rhythms, heart failure, sudden cardiac arrest, stroke, and premature death.Each of the heart defects associated with CCHD affects the flow of blood into, out of, or through the heart. Some of the heart defects involve structures within the heart itself, such as the two lower chambers of the heart (the ventricles) or the valves that control blood flow through the heart. Others affect the structure of the large blood vessels leading into and out of the heart (including the aorta and pulmonary artery). Still others involve a combination of these structural abnormalities.People with CCHD have one or more specific heart defects. The heart defects classified as CCHD include coarctation of the aorta, double-outlet right ventricle, D-transposition of the great arteries, Ebstein anomaly, hypoplastic left heart syndrome, interrupted aortic arch, pulmonary atresia with intact septum, single ventricle, total anomalous pulmonary venous connection, tetralogy of Fallot, tricuspid atresia, and truncus arteriosus."}
{"medgen_id":"C1708349","type":"Disease","keywords":["Hereditary cancer syndrome","Neoplasm"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301318\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1139\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACS, 2007\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"17392385\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASCO, 2010\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"20065170\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"IGCLC, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2991043\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"Klujit et al., 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22388873\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG/NSGC, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25394175\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACG, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25645574\",\"@Source\":\"PubMed\"}}]}","alternate_names":["Hereditary diffuse gastric adenocarcinoma"],"attribute_content":[],"alternate_symbols":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007648\"}","{\"db\":\"OMIM\",\"id\":\"137215\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"26106\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007648\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hereditary diffuse gastric adenocarcinoma\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hereditary+diffuse+gastric+cancer/8514\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1139\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"137215\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"symbol":"HDGC","id":"1360","name":"Hereditary diffuse gastric cancer","public_definition":"Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant susceptibility for diffuse gastric cancer, a poorly differentiated adenocarcinoma that infiltrates into the stomach wall causing thickening of the wall (linitis plastica) without forming a distinct mass. Diffuse gastric cancer is also referred to as signet ring carcinoma or isolated cell-type carcinoma. The average age of onset of HDGC is 38 years (range: 14-69 years). The majority of the cancers in individuals with a CDH1 pathogenic variant occur before age 40 years. The estimated cumulative risk of gastric cancer by age 80 years is 70% for men and 56% for women. Women are also at a 42% risk for lobular breast cancer."}
